There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX) and MyoKardia Inc (MYOK) with bullish sentiments.
Argenx Se (ARGX)
In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Argenx Se. The company’s shares closed yesterday at $120.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.4% and a 41.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Argenx Se is a Strong Buy with an average price target of $151.67, representing a 26.4% upside. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $154 price target.
See today’s analyst top recommended stocks >>
MyoKardia Inc (MYOK)
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on MyoKardia Inc, with a price target of $73. The company’s shares closed yesterday at $47.95.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.5% and a 52.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MyoKardia Inc with a $85 average price target, implying a 77.3% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $90 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
